N C H S - FASTATS - Alzheimers Disease
N C H S - FASTATS - Alzheimers Disease

Alzheimer's Disease Information Page: National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer's Disease Information Page: National Institute of Neurological Disorders and Stroke (NINDS)

Alzheimer's Disease Fact Sheet
Alzheimer's Disease Fact Sheet

Alzheimer disease - Genetics Home Reference
The early-onset forms of Alzheimer Disease are caused by gene mutations that can be passed from parent to child. Researchers have identified three genes that cause these forms of the disorder. Mutations in the APP gene cause Alzheimer Disease type 1. Changes in the PSEN1 gene are responsible for Alzheimer Disease type 3, while PSEN2 mutations lead to Alzheimer Disease type 4. As a result of mutations in any of these genes, large amounts of a toxic protein fragment called amyloid beta peptide are produced in the brain. This toxic peptide can build up in the brain to form clumps called amyloid plaques, which are characteristic of Alzheimer Disease. Amyloid plaques may lead to the death of nerve cells and the progressive signs and symptoms of this disorder.

Alzheimer's Home
Alzheimer's Home

Alzheimer's Disease
Alzheimer's Disease

NIHSeniorHealth: Alzheimer's Disease - Table of contents
NIHSeniorHealth: Alzheimer's Disease - Table of contents

Early Alzheimer's Disease. Clinical Practice Guideline, Number 19, Consumer Version
Early Alzheimer's Disease. Clinical Practice Guideline, Number 19, Consumer Version

MedlinePlus: Alzheimer's Disease
Does Statin Use Decrease the Amount of Alzheimer Disease Pathology in the Brain?

NIH - Alzheimer's Disease
NIH - Alzheimer's Disease

Alzheimer's Disease
Alzheimer's Disease

OMIM - ALZHEIMER DISEASE; AD
OMIM - Alzheimer Disease; AD

Alzheimers Resource Room>Facts about Alzheimer's Disease
Alzheimers Resource Room>Facts about Alzheimer's Disease

Alzheimer's: Searching for a Cure
Alzheimer's: Searching for a Cure

MedlinePlus Medical Encyclopedia: Alzheimer’s disease
MedlinePlus Medical Encyclopedia: Alzheimer’s Disease

Mental Health: A Report of the Surgeon General - Chapter 5
Mental Health: A Report of the Surgeon General - Chapter 5

ClinicalTrials.gov - Information on Clinical Trials and Human Research Studies: Trial List
GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer s Disease

Search of: "Alzheimer Disease" - List Results - ClinicalTrials.gov
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-Amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Alzheimer Disease Overview -- GeneReviews -- NCBI Bookshelf
Diagnosis/ testing. Establishing the diagnosis of Alzheimer Disease relies upon clinical-neuropathologic assessment. Neuropathologic findings of -amyloid plaques and intraneuronal neurofibrillary tangles remain the gold standard for diagnosis. The clinical diagnosis of AD, based on signs of slowly progressive dementia and findings of gross cerebral cortical atrophy on neuroimaging, is correct about 80%-90% of the time. The association of the APOE e4 allele with AD is significant; however, APOE genotyping is neither fully specific nor sensitive. While APOE genotyping may have an adjunct role in the diagnosis of AD in symptomatic individuals, it appears to have no role at this time in predictive testing of asymptomatic individuals. Three forms of early-onset familial AD (EOFAD) caused by mutations in one of three genes (APP , PSEN1 , PSEN2) are recognized. Molecular genetic testing of the three genes is available in clinical laboratories.

NIHSeniorHealth: Alzheimer's Disease - Frequently Asked Questions
NIHSeniorHealth: Alzheimer's Disease - Frequently Asked Questions

• Disease
• Dementia, Alzheimer Type
• Behavioral Symptoms